While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Photo by Artem Podrez on Pexels Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did nothing. Actually fini ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that the defendants made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to inflated stock prices for Ultragenyx [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Aquestive and its executives failed to disclose significant deficiencies in the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [5]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [6]. Group 3: Firm Background and Outreach - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Aquestive's conduct [8].

Core Insights - The drug discovery process is inefficient, requiring an average of 2,500 compounds and over four years to find one candidate for clinical trials [2][4] - Artificial intelligence (AI) is transforming drug discovery by analyzing large datasets and speeding up the identification of promising compounds [3] Company Summaries Recursion Pharmaceuticals - Recursion Pharmaceuticals has improved the drug discovery process, averaging 330 compounds synthesized in 17 months compared to the industry average [4] - The company utilizes a drug development operating system that integrates robotic labs, large biological datasets, and AI models, with proprietary datasets valued at $213 million from Roche and Genentech [5] - For full-year 2025, Recursion's revenue is projected at $74.7 million, with five clinical programs in progress and a cash runway extending into 2028 [6] - The company has demonstrated clinical proof-of-concept with a 43% median reduction in polyp burden for Familial Adenomatous Polyposis patients [6] Tempus AI - Tempus AI has developed a vast library of clinical and molecular data to enhance precision medicine, focusing on oncology, diagnostics, and genomics [8] - The company reported trailing revenue of $1.27 billion, growing approximately 30% annually, with a strong data engine driven by diagnostics [9] - Tempus is currently unprofitable with a net loss of $245 million, but analysts project nearly 30% annual revenue growth over the next three years [12] Industry Context - The healthcare industry in the U.S. is valued at $4.7 trillion, and advancements in AI could significantly change drug discovery and disease diagnosis [13] - Both Recursion Pharmaceuticals and Tempus AI are positioned to become integral parts of the evolving healthcare infrastructure [13][14]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of directors and management of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) on behalf of its investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if the Verrica board has breached its fiduciary duties to shareholders [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [2]. Group 2: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Group 1 - X-energy has filed for an initial public offering (IPO) in the United States, aiming to capitalize on increasing investor interest in nuclear power [1] - The company intends to list its Class A common stock on the Nasdaq under the ticker symbol "XE" [1] - Specific details regarding the number of shares to be offered and the price range have not been disclosed [2]

Core Viewpoint - EyePoint Inc has filed a lawsuit against Ocular Therapeutix, alleging the spread of false or misleading information regarding EyePoint's lead experimental eye drug, Duravyu [1][2]. Group 1: Legal Actions - The lawsuit was filed in Middlesex County Superior Court, Massachusetts, accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of consumer protection law [2][3]. - EyePoint is seeking a court order to stop Ocular Therapeutix from making the alleged false statements, demand a public retraction, and claim monetary damages and legal fees [3]. Group 2: Product Development - EyePoint's Duravyu is currently undergoing late-stage studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema, with data for wet AMD expected to be available by mid-2026 [4]. - Ocular Therapeutix's leading drug, Axpaxli, recently met the main goal of a key late-stage trial, demonstrating its effectiveness in helping patients with wet AMD maintain vision compared to Regeneron's Eylea [4].

Sio Capital Management disclosed a new position in Organon (OGN 3.91%) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end.What happenedAccording to a filing with the U.S. Securities and Exchange Commission dated February 17, 2026, Sio Capital Management established a new position in Organon (OGN 3.91%), purchasing 3,421,765 shares. The reported position value at quarter-end increased by $24.53 million as a result of the purchase.What else to knowThis is a new position for ...

Core Viewpoint - Rosen Law Firm is urging investors of Beyond Meat, Inc. (NASDAQ: BYND) to participate in a class action lawsuit due to allegations of misleading statements regarding the company's business operations and financial health [1][2]. Group 1: Allegations and Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and November 11, 2025, claiming that Beyond Meat made false and misleading statements [1][3]. - Allegations include that the book value of certain long-lived assets exceeded their fair value, indicating a likely material, non-cash impairment charge, which could affect the company's ability to file timely reports with the SEC [3]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true details became public [3]. Group 2: Participation and Legal Representation - Shareholders interested in serving as lead plaintiffs must file motions by March 24, 2026, and can choose to remain absent class members without participating in the case [4]. - Rosen Law Firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless they recover losses [5][6]. - The firm has a strong track record, having recovered over $1 billion for shareholders since its inception [6].